search
Back to results

Growth and Nutritional Status of Very Low Birth Weight Infants Fed a High Protein Exclusive Human Milk Diet (MedolacHMF)

Primary Purpose

Premature Infant, Breast Milk Expression

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Human milk based human milk fortifier
Sponsored by
Augusta University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Premature Infant focused on measuring premature infant, breast milk, breastmilk, human milk, human milk fortifier

Eligibility Criteria

23 Weeks - 33 Weeks (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Birth weight 750-1800 grams
  2. Admitted to AU NICU within 24 hours of life
  3. Estimated gestational age (EGA) 23 to 33 weeks as confirmed by the Ballard score
  4. Birth weight appropriate for gestational age (AGA) defined as >3rd% on a gender-specific Fenton growth curve (Fenton 2013, Calgary, Canada)
  5. Enteral feedings initiated within 7 days of life
  6. Breastmilk diet, maternal or donor milk

Exclusion Criteria:

  1. Renal conditions affecting electrolyte metabolism and/or excretion
  2. Gastro-intestinal conditions that preclude feeding or affect nutrient absorption (gastroschisis, omphalocele)
  3. EGA >33 weeks or birth weight >1800 grams or EGA <23 weeks or birth weight <750 grams
  4. Apgar <3 at 5 minutes
  5. Grade 3 or higher intraventricular hemorrhage (IVH)
  6. Intrauterine growth restriction (IUGR), as defined as <3rd% on a gender-specific Fenton growth curve
  7. Congenital anomalies including congenital heart disease or other major defect requiring surgical intervention
  8. Intake of cow's milk formula or fortifier before or after the initiation of the study protocol

Sites / Locations

  • Augusta University

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Retrospective Chart Review

Prospective

Arm Description

Retrospective Chart Review for historical controls. Historic controls fed cow's milk fortifier

All neonates with birth weights ranging from 750-1500 grams and gestational ages 23-33 weeks admitted to the NICU at Augusta University within 24 hours of life will be eligible for screening within 72 hours of admission and upon parent's or legal guardian's consent. Infants will be fed a human milk fortifier made with donor human milk. Data will be compared with historic control data.

Outcomes

Primary Outcome Measures

Return to birth weight day
Day of life infant returns to birth weight
Growth Velocity
rate of weight gain measured as g/kg/day
Mean Serum Magnesium
Serum and urine Magnesium
Mean Serum CO2
Serum CO2

Secondary Outcome Measures

Mean z-scores
z-scores for weight, length, and head circumference
Mean serum Vitamin D, 1 25 (OH) 2D
serum Vitamin D
Mean serum parathyroid Hormone (PTH)
Serum PTH
Mean serum Sodium
Serum and urine Sodium
Mean serum Blood Urea Nitrogen (BUN)
serum BUN
Mean serum Calcium
serum Calcium
Mean serum Phosphorus
serum Phosphorus
Mean serum Alkaline Phosphatase
serum Alkaline Phosphatase
Mean serum Hemoglobin
serum Hemoglobin
Mean serum Potassium
serum and urine Potassium
Mean serum Hematocrit
serum Hematocrit

Full Information

First Posted
February 11, 2019
Last Updated
July 25, 2019
Sponsor
Augusta University
Collaborators
Neolac Inc dba Medolac Laboratories
search

1. Study Identification

Unique Protocol Identification Number
NCT03839173
Brief Title
Growth and Nutritional Status of Very Low Birth Weight Infants Fed a High Protein Exclusive Human Milk Diet
Acronym
MedolacHMF
Official Title
Growth and Nutritional Status of Very Low Birth Weight Infants Fed a High Protein Exclusive Human Milk Diet
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Unknown status
Study Start Date
July 25, 2019 (Anticipated)
Primary Completion Date
March 31, 2020 (Anticipated)
Study Completion Date
March 31, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Augusta University
Collaborators
Neolac Inc dba Medolac Laboratories

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this two-arm investigation is to determine if growth patterns of very low birth weight infants (VLBW) (birth weight 750-1500 grams) fed human milk (maternal or donor) supplemented with a human milk-based fortifier grow according to established guidelines and maintain adequate micronutrient levels.
Detailed Description
To achieve this goal, the investigators will prospectively analyze the growth and micronutrient status of VLBW infants who are fed human milk (maternal or donor) supplemented with a human-milk-based fortifier with increased protein (Medolac® Human Milk Fortifier). In addition, the investigators will compare the findings to retrospectively collected data for growth rates and micronutrient status of infants who received human milk fortified with cow's milk -based fortifier (Enfamil® Hydrolyzed Liquid Human Milk Fortifier). The investigators hypothesize that a human milk-based fortifier with increased protein will support growth at recommended levels (weight gain of 12-18 g/kg/day, head circumference 0.75-1.0 cm/week, length 0.8-1.1 cm/week)[1-3] and prevent micronutrient deficiency in the VLBW infant Aim 1: To determine if VLBW infants fed human milk, maternal or donor, supplemented with a human milk-based fortifier with increased protein grow at recommended levels for weight, length, and head circumference. To achieve this aim, Z-scores for weight, length, and head circumference will be tracked. Measurements will be taken at birth and then weekly until 36 weeks post-menstrual age (PMA) or discharge from the neonatal intensive care unit (NICU), whichever comes first. Aim 2: To measure nutritional status in VLBW premature infants fed human milk supplemented with a human milk-based fortifier with increased protein. To achieve this aim, serum magnesium, potassium, chloride, blood urea nitrogen (BUN), creatinine, sodium, calcium, phosphorus, CO2, Vitamin D 1, 25 (OH) 2D, parathyroid hormone (PTH), alkaline phosphatase, hemoglobin, hematocrit will be measured within 24 hours of reaching full enteral feedings and repeated seven days later, and then every fourteen days until 36 weeks PMA or discharge, whichever comes first. Urine magnesium and sodium will be measured on the same schedule. Aim 3: To compare growth rates and nutritional status of VLBW infants fed human milk fortified with a human milk-based fortifier to growth rates and nutritional status of those fed human milk fortified with a cow's milk-based fortifier.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premature Infant, Breast Milk Expression
Keywords
premature infant, breast milk, breastmilk, human milk, human milk fortifier

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
51 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Retrospective Chart Review
Arm Type
No Intervention
Arm Description
Retrospective Chart Review for historical controls. Historic controls fed cow's milk fortifier
Arm Title
Prospective
Arm Type
Experimental
Arm Description
All neonates with birth weights ranging from 750-1500 grams and gestational ages 23-33 weeks admitted to the NICU at Augusta University within 24 hours of life will be eligible for screening within 72 hours of admission and upon parent's or legal guardian's consent. Infants will be fed a human milk fortifier made with donor human milk. Data will be compared with historic control data.
Intervention Type
Other
Intervention Name(s)
Human milk based human milk fortifier
Intervention Description
A human milk fortifier with added minerals made from donor human milk
Primary Outcome Measure Information:
Title
Return to birth weight day
Description
Day of life infant returns to birth weight
Time Frame
birth to 30 days
Title
Growth Velocity
Description
rate of weight gain measured as g/kg/day
Time Frame
Weekly until 36 weeks post menstrual age or discharge
Title
Mean Serum Magnesium
Description
Serum and urine Magnesium
Time Frame
Every 14 days until 36 weeks post menstrual age or discharge
Title
Mean Serum CO2
Description
Serum CO2
Time Frame
Every 14 days until 36 weeks post menstrual age or discharge
Secondary Outcome Measure Information:
Title
Mean z-scores
Description
z-scores for weight, length, and head circumference
Time Frame
Weekly until 36 weeks post menstrual age or discharge
Title
Mean serum Vitamin D, 1 25 (OH) 2D
Description
serum Vitamin D
Time Frame
Every 14 days until 36 weeks post menstrual age or discharge
Title
Mean serum parathyroid Hormone (PTH)
Description
Serum PTH
Time Frame
Every 14 days until 36 weeks post menstrual age or discharge
Title
Mean serum Sodium
Description
Serum and urine Sodium
Time Frame
Every 14 days until 36 weeks post menstrual age or discharge
Title
Mean serum Blood Urea Nitrogen (BUN)
Description
serum BUN
Time Frame
Every 14 days until 36 weeks post menstrual age or discharge
Title
Mean serum Calcium
Description
serum Calcium
Time Frame
Every 14 days until 36 weeks post menstrual age or discharge
Title
Mean serum Phosphorus
Description
serum Phosphorus
Time Frame
Every 14 days until 36 weeks post menstrual age or discharge
Title
Mean serum Alkaline Phosphatase
Description
serum Alkaline Phosphatase
Time Frame
Every 14 days until 36 weeks post menstrual age or discharge
Title
Mean serum Hemoglobin
Description
serum Hemoglobin
Time Frame
Every 14 days until 36 weeks post menstrual age or discharge
Title
Mean serum Potassium
Description
serum and urine Potassium
Time Frame
Every 14 days until 36 weeks post menstrual age or discharge
Title
Mean serum Hematocrit
Description
serum Hematocrit
Time Frame
Every 14 days until 36 weeks post menstrual age or discharge

10. Eligibility

Sex
All
Minimum Age & Unit of Time
23 Weeks
Maximum Age & Unit of Time
33 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Birth weight 750-1800 grams Admitted to AU NICU within 24 hours of life Estimated gestational age (EGA) 23 to 33 weeks as confirmed by the Ballard score Birth weight appropriate for gestational age (AGA) defined as >3rd% on a gender-specific Fenton growth curve (Fenton 2013, Calgary, Canada) Enteral feedings initiated within 7 days of life Breastmilk diet, maternal or donor milk Exclusion Criteria: Renal conditions affecting electrolyte metabolism and/or excretion Gastro-intestinal conditions that preclude feeding or affect nutrient absorption (gastroschisis, omphalocele) EGA >33 weeks or birth weight >1800 grams or EGA <23 weeks or birth weight <750 grams Apgar <3 at 5 minutes Grade 3 or higher intraventricular hemorrhage (IVH) Intrauterine growth restriction (IUGR), as defined as <3rd% on a gender-specific Fenton growth curve Congenital anomalies including congenital heart disease or other major defect requiring surgical intervention Intake of cow's milk formula or fortifier before or after the initiation of the study protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amy Gates, RD
Organizational Affiliation
Augusta University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Augusta University
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30912
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
16585322
Citation
Ehrenkranz RA, Dusick AM, Vohr BR, Wright LL, Wrage LA, Poole WK. Growth in the neonatal intensive care unit influences neurodevelopmental and growth outcomes of extremely low birth weight infants. Pediatrics. 2006 Apr;117(4):1253-61. doi: 10.1542/peds.2005-1368.
Results Reference
background
PubMed Identifier
23601190
Citation
Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 2013 Apr 20;13:59. doi: 10.1186/1471-2431-13-59.
Results Reference
background
PubMed Identifier
22371471
Citation
Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics. 2012 Mar;129(3):e827-41. doi: 10.1542/peds.2011-3552. Epub 2012 Feb 27.
Results Reference
background
Citation
Koletsko B PB, Uauy R. Nutritional Care of Preterm Infants. Basel, Switzerland: Karger, 2014.
Results Reference
background
PubMed Identifier
26488118
Citation
Kim JH, Chan G, Schanler R, Groh-Wargo S, Bloom B, Dimmit R, Williams L, Baggs G, Barrett-Reis B. Growth and Tolerance of Preterm Infants Fed a New Extensively Hydrolyzed Liquid Human Milk Fortifier. J Pediatr Gastroenterol Nutr. 2015 Dec;61(6):665-71. doi: 10.1097/MPG.0000000000001010. Erratum In: J Pediatr Gastroenterol Nutr. 2016 Jan;62(1):188-9.
Results Reference
background
PubMed Identifier
22987877
Citation
Moya F, Sisk PM, Walsh KR, Berseth CL. A new liquid human milk fortifier and linear growth in preterm infants. Pediatrics. 2012 Oct;130(4):e928-35. doi: 10.1542/peds.2011-3120. Epub 2012 Sep 17.
Results Reference
background
PubMed Identifier
20036378
Citation
Sullivan S, Schanler RJ, Kim JH, Patel AL, Trawoger R, Kiechl-Kohlendorfer U, Chan GM, Blanco CL, Abrams S, Cotten CM, Laroia N, Ehrenkranz RA, Dudell G, Cristofalo EA, Meier P, Lee ML, Rechtman DJ, Lucas A. An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products. J Pediatr. 2010 Apr;156(4):562-7.e1. doi: 10.1016/j.jpeds.2009.10.040. Epub 2009 Dec 29.
Results Reference
background
Citation
Gates A BJ. [Neonatal Outcomes Augusta Univeristy NICU] Unpublished raw data. Augusta 2017.
Results Reference
background
PubMed Identifier
20732945
Citation
Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, Hale EC, Newman NS, Schibler K, Carlo WA, Kennedy KA, Poindexter BB, Finer NN, Ehrenkranz RA, Duara S, Sanchez PJ, O'Shea TM, Goldberg RN, Van Meurs KP, Faix RG, Phelps DL, Frantz ID 3rd, Watterberg KL, Saha S, Das A, Higgins RD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010 Sep;126(3):443-56. doi: 10.1542/peds.2009-2959. Epub 2010 Aug 23.
Results Reference
background
PubMed Identifier
24394538
Citation
Thoene M, Hanson C, Lyden E, Dugick L, Ruybal L, Anderson-Berry A. Comparison of the effect of two human milk fortifiers on clinical outcomes in premature infants. Nutrients. 2014 Jan 3;6(1):261-75. doi: 10.3390/nu6010261.
Results Reference
background
PubMed Identifier
28637062
Citation
Kumar N, Monga R, Sampath V, Ehrhart B. Prospective Comparison of Enfamil and Similac Liquid Human Milk Fortifier on Clinical Outcomes in Premature Infants. Am J Perinatol. 2017 Dec;34(14):1411-1416. doi: 10.1055/s-0037-1603940. Epub 2017 Jun 21. No abstract available.
Results Reference
background
PubMed Identifier
23968744
Citation
Cristofalo EA, Schanler RJ, Blanco CL, Sullivan S, Trawoeger R, Kiechl-Kohlendorfer U, Dudell G, Rechtman DJ, Lee ML, Lucas A, Abrams S. Randomized trial of exclusive human milk versus preterm formula diets in extremely premature infants. J Pediatr. 2013 Dec;163(6):1592-1595.e1. doi: 10.1016/j.jpeds.2013.07.011. Epub 2013 Aug 20.
Results Reference
background
PubMed Identifier
6848932
Citation
Gross SJ. Growth and biochemical response of preterm infants fed human milk or modified infant formula. N Engl J Med. 1983 Feb 3;308(5):237-41. doi: 10.1056/NEJM198302033080501.
Results Reference
background
PubMed Identifier
19881390
Citation
Agostoni C, Buonocore G, Carnielli VP, De Curtis M, Darmaun D, Decsi T, Domellof M, Embleton ND, Fusch C, Genzel-Boroviczeny O, Goulet O, Kalhan SC, Kolacek S, Koletzko B, Lapillonne A, Mihatsch W, Moreno L, Neu J, Poindexter B, Puntis J, Putet G, Rigo J, Riskin A, Salle B, Sauer P, Shamir R, Szajewska H, Thureen P, Turck D, van Goudoever JB, Ziegler EE; ESPGHAN Committee on Nutrition. Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2010 Jan;50(1):85-91. doi: 10.1097/MPG.0b013e3181adaee0.
Results Reference
background
PubMed Identifier
26179961
Citation
Ong KK, Kennedy K, Castaneda-Gutierrez E, Forsyth S, Godfrey KM, Koletzko B, Latulippe ME, Ozanne SE, Rueda R, Schoemaker MH, van der Beek EM, van Buuren S, Fewtrell M. Postnatal growth in preterm infants and later health outcomes: a systematic review. Acta Paediatr. 2015 Oct;104(10):974-86. doi: 10.1111/apa.13128.
Results Reference
background
PubMed Identifier
22534258
Citation
Ghandehari H, Lee ML, Rechtman DJ; H2MF Study Group. An exclusive human milk-based diet in extremely premature infants reduces the probability of remaining on total parenteral nutrition: a reanalysis of the data. BMC Res Notes. 2012 Apr 25;5:188. doi: 10.1186/1756-0500-5-188.
Results Reference
background
PubMed Identifier
24922980
Citation
Food and Drug Administration, HHS. Current good manufacturing practices, quality control procedures, quality factors, notification requirements, and records and reports, for infant formula. Final rule. Fed Regist. 2014 Jun 10;79(111):33057-72.
Results Reference
background

Learn more about this trial

Growth and Nutritional Status of Very Low Birth Weight Infants Fed a High Protein Exclusive Human Milk Diet

We'll reach out to this number within 24 hrs